Verona Pharma (VRNA) to Release Quarterly Earnings on Thursday

Verona Pharma (NASDAQ:VRNA) is set to release its earnings data before the market opens on Thursday, August 8th. Analysts expect Verona Pharma to post earnings of ($0.35) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.08). On average, analysts expect Verona Pharma to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verona Pharma Stock Up 4.0 %

VRNA opened at $20.96 on Wednesday. Verona Pharma has a twelve month low of $11.39 and a twelve month high of $23.72. The company has a debt-to-equity ratio of 0.22, a quick ratio of 18.40 and a current ratio of 18.40. The business has a 50 day moving average price of $17.19 and a 200 day moving average price of $16.46. The firm has a market cap of $1.69 billion, a P/E ratio of -27.22 and a beta of 0.44.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Piper Sandler upped their price objective on shares of Verona Pharma from $31.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, April 16th. Canaccord Genuity Group upped their price target on shares of Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday, July 22nd. Truist Financial raised their price target on Verona Pharma from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, June 28th. Finally, HC Wainwright boosted their price objective on Verona Pharma from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $36.00.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.